A Y Combinator-backed startup just raised $39 million to develop new psychedelic treatments for depression

Dec 15 2022 by Business Insider

 
Jonathan Sporn is the founder and CEO of Gilgamesh Pharmaceuticals.

Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals wants to develop the next generation of psychedelic medicines. The company is creating psychedelic drugs that work faster and may not have hallucinogenic effects. The company just raised $39 million from investors and plans to start clinical trials next year.

Gilgamesh Pharmaceuticals is trying to develop a new type of psychedelic medicine — one that has all the mental...

Continue Reading A Y Combinator-backed startup just raised $39 million to develop new psychedelic treatments for depression